Zybev Injection (Bevacizumab): Premium Anti-Angiogenic Biological Therapy – Global Supply by Ernest Oncology In the evolving oncology landscape of 2026, Zybev Injection (active ingredient Bevacizumab) has solidified its position as a critical biosimilar for the management of advanced solid tumors. As a recombinant humanized monoclonal antibody, Zybev provides clinical efficacy equivalent to the reference biologic, targeting the Vascular Endothelial Growth Factor (VEGF) to inhibit tumor-induced angiogenesis and arrest cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Zybev to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Zybev (Bevacizumab) Zybev is a biological therapy administered via intravenous (IV) infusion, designed to disrupt the blood supply that tumors require to grow and metastasize. Product Specifications Active Ingredient: Bevacizumab (Biosimilar) Available Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials Pharmacological Class: Vascular Endothelial Growth Factor (VEGF) Inhibitor; Monoclonal Antibody Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Used as a foundational treatment in combination with fluoropyrimidine-based chemotherapy. Non-Small Cell Lung Cancer (NSCLC): First-line treatment for unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Glioblastoma: For the treatment of recurrent glioblastoma in adult patients. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa. Ovarian & Cervical Cancers: Effective in persistent, recurrent, or metastatic cases when combined with specific chemotherapy regimens. Mechanism of Action: The Anti-Angiogenic Approach Zybev works by selectively binding to the VEGF protein, preventing it from interacting with its receptors on the surface of endothelial cells. Angiogenesis Inhibition: By neutralizing VEGF, Zybev prevents the formation of new blood vessels that tumors need for nutrients and oxygen. Vascular Regression: Existing tumor microvasculature undergoes regression, inhibiting tumor growth. Vascular Normalization: It helps normalize the remaining tumor vasculature, reducing interstitial fluid pressure and potentially improving the delivery of co-administered chemotherapy. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in navigating the strict regulatory and logistical requirements for shipping temperature-sensitive biosimilars from India to major international hubs. United Kingdom & London: We supply NHS trusts and private oncology clinics in London, adhering to all MHRA biological import protocols. United States: Bulk supply for hospital networks and specialty wholesalers seeking cost-effective, high-quality Bevacizumab biosimilars from India. Abu Dhabi & UAE: Supporting the UAE’s world-class healthcare sector with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology biologics and anti-angiogenic biosimilars. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Bevatas Injection (Bevacizumab): Targeted Anti-Angiogenic Therapy for Advanced Oncology – Global Supply by Ernest Oncology In the advanced clinical landscape of 2026, Bevatas Injection (active ingredient Bevacizumab) stands as a pivotal biological therapy for the management of various solid tumors. As a recombinant humanized monoclonal antibody and a highly regulated biosimilar, Bevatas offers a cost-effective yet clinically equivalent alternative to reference biologics, specifically targeting the Vascular Endothelial Growth Factor (VEGF) to inhibit tumor-induced angiogenesis. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Bevatas to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain management and rapid logistical execution. Technical Product Information: Bevatas Injection Bevatas is a sterile, clear to slightly opalescent, colorless to pale brown solution for intravenous (IV) infusion after appropriate dilution. Product Specifications Active Ingredient: Bevacizumab (Biosimilar) Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials Pharmacological Class: Antineoplastic; Monoclonal Antibody; VEGF Inhibitor Storage Requirements: Store at 2°C to 8°C (36°F to 46°F). Strictly requires validated Cold Chain Logistics. Do not freeze or shake. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): First or second-line treatment in combination with 5-fluorouracil-based chemotherapy. Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, or metastatic non-squamous NSCLC. Glioblastoma: For the treatment of recurrent glioblastoma in adult patients. Metastatic Renal Cell Carcinoma (mRCC): Used in combination with interferon alfa. Cervical & Ovarian Cancer: Effective in persistent, recurrent, or metastatic cases when combined with standard chemotherapy protocols. Mechanism of Action: Arresting Tumor Blood Supply Bevatas exerts its therapeutic effect by specifically binding to the VEGF protein, preventing it from interacting with its receptors on the surface of endothelial cells. Neutralization of VEGF: By sequestering VEGF, Bevatas prevents the growth signals required for the formation of new blood vessels. Vascular Regression: Existing tumor microvasculature undergoes regression, effectively “starving“ the tumor of essential nutrients and oxygen. Normalization of Tumor Vasculature: Bevatas helps normalize remaining tumor vessels, reducing high interstitial fluid pressure and potentially improving the delivery of concurrent chemotherapy. Inhibition of Metastasis: By limiting the vascular network, the drug reduces the pathways through which cancer cells can spread to distant organs. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biosimilars from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS Trusts and private oncology centers in London, adhering to all MHRA biological import protocols and technical documentation standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced oncology care. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import frameworks. South Africa: Strengthening the African oncology sector with high-quality, cost-effective biosimilars from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Avastin Injection (Bevacizumab): The Standard in Anti-Angiogenic Cancer Therapy – Global Supply by Ernest Oncology In the oncology landscape of 2026, Avastin (active ingredient Bevacizumab) remains one of the most versatile and critical biological agents in clinical use. As a recombinant humanized monoclonal antibody, Avastin has revolutionized the treatment of multiple solid tumors by targeting the vascular endothelial growth factor (VEGF), effectively “starving“ tumors of the blood supply they need to grow and spread. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Avastin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain management and rapid global delivery. Technical Product Profile: Avastin (Bevacizumab) Avastin is a solution for intravenous (IV) infusion that selectively binds to and neutralizes the biologic activity of human VEGF. Product Specifications Active Ingredient: Bevacizumab Common Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials Pharmacological Class: Antineoplastic Agent; Monoclonal Antibody; VEGF Inhibitor Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Used as a first-line or second-line treatment in combination with fluoropyrimidine-based chemotherapy. Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC. Glioblastoma: For the treatment of recurrent glioblastoma in adults. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa. Cervical and Ovarian Cancers: Effective in persistent, recurrent, or metastatic cases in combination with specific chemotherapy regimens. Mechanism of Action: Inhibiting Tumor Angiogenesis Avastin works through a unique process called anti-angiogenesis. VEGF Neutralization: Avastin binds to VEGF, a protein that stimulates the growth of new blood vessels. Vascular Regression: By blocking VEGF, Avastin causes the regression of existing tumor microvasculature. Inhibition of New Growth: It prevents the formation of new blood vessels (angiogenesis), which is essential for tumor growth beyond a few millimeters. Enhanced Chemotherapy Delivery: By normalizing tumor vascular permeability, it can improve the delivery of co-administered chemotherapeutic agents to the tumor core. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-quality biological medications. United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced cancer care. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383